Lp(a) was once again the focus of multiple presentations at the National Lipid Association Annual Scientific Sessions (Las Vegas, USA, 30 May-2 June 2024), with the emphasis on raising awareness about the importance of Lp(a) as a major risk factor for atherosclerotic cardiovascular disease and the need to change attitudes and break down barriers to […]
A family history of atherosclerotic cardiovascular disease (ASCVD) may be a useful indicator of elevated Lp(a) level and the need for Lp(a) targeted risk assessment. This is the conclusion from an analysis of data on 4,244 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) who had Lp(a) measurements and detailed family history information from completed […]
Provider hesitation in testing for Lp(a) in clinical practice has been identified in more than two thirds of respondents to a survey of University of Pennsylvania Health Systems (UPHS), providers of cardiology, neurology, primary care, and vascular surgery.
Lp(a) is a useful biomarker for helping to identify patients with well controlled LDL-C who are still at risk of coronary artery disease (CAD), according to data from the Young Heart study of patients <60 years with CAD.
Lp(a) is among the serum lipoproteins that are significantly increased in patients with pre-eclampsia. Samples taken during the Child Health Advances from Research with Mothers (CHARM) study at 89 and 189 gestational days showed significantly higher levels of direct LDL-C (+ 10%), small dense LDL-C (+ 18%), apoB (+ 10%), and Lp(a) (+ 50%) in […]
Increasing levels of circulating PCSK9 are associated with higher levels of circulating Lp(a), driven by small Lp(a) particles (≤24 Kringle IV type 2 repeats) – consistent with a mechanistic hypothesis that the PCSK9/LDL receptor axis may be involved in the metabolism of small but not large Lp(a) particles.
